TCL1A and B-cell chronic lymphocytic leukemia: Further work by Daneshmanesh et al. in primary CLL samples treated with antibodies directed toward ROR1 enforced the role of TCL1 as a co-activator of the PI3K/AKT/mTOR pathway via direct contact with AKTs and indirectly through ROR1 (29).